Nicotinamide N-oxidation by CYP2E1 in human liver microsomes

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 550-553

  Pissios, Pavlos ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 2E1; DIETHYLTHIOCARBAMATE; DRUG METABOLITE; FLUCONAZOLE; KETOCONAZOLE; NICOTINAMIDE; NICOTINAMIDE N OXIDE; ORPHENADRINE; QUINIDINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG OXIDATION; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL;

BIOTRANSFORMATION; CATALYSIS; CYTOCHROME P-450 CYP2E1; ENZYME INHIBITORS; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; NIACINAMIDE; OXIDATION-REDUCTION; SUBSTRATE SPECIFICITY; VITAMIN B COMPLEX;

EID: 84874069082     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049734     Document Type: Article

References (34)

1. Bartus M, ?omnicka M, Kostogrys RB, Kazmierczak P, Wata?a C, S?ominska EM, Smolenski RT, Pisulewski PM, Adamus J, and Gebicki J, et al. (2008) 1-Methylnicotinamide (MNA) prevents endothelial dysfunction in hypertriglyceridemic and diabetic rats. Pharmacol Rep 60: 127-138.
2. Bogan KL and Brenner C (2008) Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 28:115-130.
3. Bonavita V, Narrod SA, and Kaplan NO (1961) Metabolites of nicotinamide in mouse urine: effects of azaserine. J Biol Chem 236:936-939.
4. Cantoni GL (1951) Methylation of nicotinamide with soluble enzyme system from rat liver. J Biol Chem 189:203-216.
5. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, and Crabb DW (2003) Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37:544-550.
6. Chaykin S, Dagani M, Johnson L, and Samli M (1965) The fate of nicotinamide in the mouse. Urinary metabolites. J Biol Chem 240:932-938.
7. Chlopicki S, Swies J, Mogielnicki A, Buczko W, Bartus M, Lomnicka M, Adamus J, and Gebicki J (2007) 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts antithrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br J Pharmacol 152:230-239.
8. Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP, McGill PJ, Holder JC, Hutton KA, and Haselden JN, et al. (2005) Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol 79:208-223.
9. Easterbrook J, Lu C, Sakai Y, and Li AP (2001) Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141-144.
10. Felsted RL and Chaykin S (1967) N1-methylnicotinamide oxidation in a number of mammals. J Biol Chem 242:1274-1279.
11. Fukuoka S-I, Ishiguro K, Yanagihara K, Tanabe A, Egashira Y, Sanada H, and Shibata K (2002) Identification and expression of a cDNA encoding human alpha-amino-beta-carboxymuconateepsilon-semialdehyde decarboxylase (ACMSD). A key enzyme for the tryptophan-niacine pathway and "quinolinate hypothesis". J Biol Chem 277:35162-35167.
12. Ghanayem BI, Wang H, and Sumner S (2000) Using cytochrome P-450 gene knock-out mice to study chemical metabolism, toxicity, and carcinogenicity. Toxicol Pathol 28:839-850.
13. Gonzalez FJ, Ueno T, Umeno M, Song BJ, Veech RL, and Gelboin HV (1991) Microsomal ethanol oxidizing system: transcriptional and posttranscriptional regulation of cytochrome P450, CYP2E1. Alcohol Alcohol Suppl 1:97-101.
14. Houtkooper RH, Cantó C, Wanders RJ, and Auwerx J (2010) The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31:194-223.
15. Iwata K, Ogata S, Okumura K, and Taguchi H (2003) Induction of differentiation in human promyelocytic leukemia HL-60 cell line by niacin-related compounds. Biosci Biotechnol Biochem 67:1132-1135.
16. Kim SG, Williams DE, Schuetz EG, Guzelian PS, and Novak RF (1988) Pyridine induction of cytochrome P-450 in the rat: role of P-450j (alcohol-inducible form) in pyridine N-oxidation. J Pharmacol Exp Ther 246:1175-1182.
17. Kobayashi K, Abe S, Nakajima M, Shimada N, Tani M, Chiba K, and Yamamoto T (1999) Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab Dispos 27:1429-1433.
18. Krueger SK and Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/ function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106:357-387.
19. Leifer E, Roth LJ, Hogness DS, and Corson MH (1951) The metabolism of radioactive nicotinic acid and nicotinamide. J Biol Chem 190:595-602.
20. Marchand LL, Wilkinson GR, and Wilkens LR (1999) Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev 8:495-500.
21. Menon RM, Adams MH, González MA, Tolbert DS, Leu JH, and Cefali EA (2007) Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 45:448-454.
22. Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, and Sonawane B (2009) Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev 12:362-388.
23. Nomura K, Shin M, Sano K, Umezawa C, and Shimada T (1983) Nicotinamide N-oxide formation by rat liver microsomes. Biochem Pharmacol 32:934-936.
24. Peng R, Tennant P, Lorr NA, and Yang CS (1983) Alterations of microsomal monooxygenase system and carcinogen metabolism by streptozotocin-induced diabetes in rats. Carcinogenesis 4:703-708.
25. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:566-573.
26. Piccoli P, Carrieri M, Padovano L, Di Mare M, Bartolucci GB, Fracasso ME, Lepera JS, and Manno M (2010) In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene. Toxicol Lett 192:29-33.
27. Sanada H (1985) Suppressive effect of dietary unsaturated fatty acids on alpha-amino-betacarboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme of tryptophan-niacin metabolism in rat liver. J Nutr Sci Vitaminol (Tokyo) 31:327-337.
28. Shibata K, Kakehi H, and Matsuo H (1990) Niacin catabolism in rodents. J Nutr Sci Vitaminol (Tokyo) 36:87-98.
29. Shin M, Kim I, Inoue Y, Kimura S, and Gonzalez FJ (2006) Regulation of mouse hepatic alphaamino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by hepatocyte nuclear factor 4alpha and peroxisome proliferator- activated receptor alpha. Mol Pharmacol 70:1281-1290.
30. Sohn OS, Ishizaki H, Yang CS, and Fiala ES (1991) Metabolism of azoxymethane, methylazoxymethanol and N-nitrosodimethylamine by cytochrome P450IIE1. Carcinogenesis 12: 127-131.
31. Stratford MR and Dennis MF (1992) High-performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urine. J Chromatogr A 582: 145-151.
32. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, and Midha KK (1997) N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 25:524-527.
33. Zhang W, Kilicarslan T, Tyndale RF, and Sellers EM (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897-902.
34. Zhen Y, Krausz KW, Chen C, Idle JR, and Gonzalez FJ (2007) Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol 21:2136-2151.